GlassScriptPhysician profile
Erik Miller
NPI 1063042596
$3,430.14
in general payments reported to CMS, 2019-2025
40 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $773 · 2023: $962 · 2024: $859 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,032.98 | 2021-2025 | |
| Pfizer INC. | $267.12 | 2023-2025 | |
| Lilly USA, LLC | $190.52 | 2021-2025 | Mounjaro, Zepbound, Reyvow |
| Glaxosmithkline, LLC. | $158.64 | 2021-2025 | Arexvy, Shingrix, Bexsero |
| Amgen INC. | $153.34 | 2023-2024 | Evenity, Prolia, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $150.57 | 2021-2024 | Airsupra, Breztri |
| Novo Nordisk INC | $141.94 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $116.70 | 2022 | |
| Antares Pharma, INC. | $88.53 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Merck Sharp & Dohme LLC | $85.71 | 2021-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Hologic Sales and Service, LLC | $73.57 | 2022-2025 | Thinprep 2000 Processor, Aptima |
| Edwards Lifesciences Corporation | $63.81 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Takeda Pharmaceuticals U.S.A., INC. | $61.61 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $58.89 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $52.35 | 2022-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.